Melanoma antigen family B6 (MAGEB6)

Melanoma antigen family B6 (MAGEB6), commonly abbreviated as MAGEB6, is part of the cancer-testis antigen gene family. These antigens are typically silent in normal tissues except for germ cells of the testis, but are aberrantly activated in a variety of malignancies[1][3]. The family is characterized by significant sequence similarity (50–68% identity among members) and variable promoters, possibly enabling differential transcriptional regulation. Members of the MAGE family—including MAGEB6—have been implicated in supporting cancer cell survival, modulating apoptosis, and interacting with tumor suppressor p53, thereby promoting immune escape and oncogenic progression[2]. MAGEB6 has high immunogenic potential, generating humoral and cytotoxic T-cell responses in cancer patients. This immunogenicity makes it a candidate for cancer immunotherapy and as a biomarker for patient selection or disease monitoring[4]. The full biological role of MAGEB6 is not completely elucidated, but—as with other MAGE proteins—its expression in tumors is linked to increased survival, cell proliferation, resistance to apoptosis, and possible metastatic progression. Disease associations include melanoma and rare sex development disorders[3]. No interacting drugs or mechanisms of action are directly linked to this specific family member as of current knowledge, though cancer-testis antigens are under active investigation for therapeutic targeting. Safety concerns center on potential immune effects due to restricted normal tissue expression (testis), which must be considered in immunotherapeutic development.

Other names

MAGE-B6CT3.4MAGEB6ACancer/testis antigen 3.4cancer/testis antigen family 3, member 4melanoma-associated antigen B6